ENTPD1 and colitis: To test this theory, the phosphodiesterase inhibitor and anti-platelet drug, dipyridamole, was used to drive the cAMP pathway in a mouse model of colitis and in patients, resulting in a dose-dependent increase in T cell CD39 expression and improved epithelial integrity and decreased colitis severity116.